Status:
COMPLETED
Naldebain for Pain Management After Knee Arthroplasty
Lead Sponsor:
Kaohsiung Medical University Chung-Ho Memorial Hospital
Conditions:
Arthropathy of Knee Joint
Eligibility:
All Genders
50-100 years
Phase:
PHASE4
Brief Summary
Naldebain, a long-acting analgesic injection, obtained a license from the Taiwan Food and Drug Administration (TFDA) of the Ministry of Health and Welfare on March 6, 2017 to approve a sustained-relea...
Detailed Description
Naldebain, a long-acting analgesic injection, obtained a license from the Taiwan Food and Drug Administration (TFDA) of the Ministry of Health and Welfare on March 6, 2017 to approve a sustained-relea...
Eligibility Criteria
Inclusion
- Age at least 50 years old, not exceed 100 years old
- Diagnosed Primary Knee Osteoarthritis accepted Knee Arthroplasty
Exclusion
- Diagnosed inflammatory Arthritis、Rheumatoid Arthritis
- Accepted Revision Knee Arthroplasty
- Patients with head injury, intracranial injury, increased intracerebral pressure and liver insufficiency
- Patients who are allergic to nalbuphine sebacate, nalbuphine, sesame oil or benzyl benzoate drugs
Key Trial Info
Start Date :
April 6 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 28 2022
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT05266027
Start Date
April 6 2022
End Date
November 28 2022
Last Update
March 27 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kaohsiung Medical University Hospital
Kaohsiung City, Taiwan, 807